Glaukos (NYSE:GKOS – Free Report) had its price objective increased by BTIG Research from $140.00 to $149.00 in a research report sent to investors on Tuesday morning,Benzinga reports. BTIG Research currently has a buy rating on the medical instruments supplier’s stock.
GKOS has been the subject of a number of other research reports. Piper Sandler set a $140.00 price target on Glaukos in a research note on Thursday, October 17th. JPMorgan Chase & Co. raised their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Truist Financial boosted their price target on shares of Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a report on Monday, October 14th. Needham & Company LLC raised their price objective on shares of Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, Wells Fargo & Company boosted their target price on shares of Glaukos from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $135.45.
Check Out Our Latest Report on GKOS
Glaukos Price Performance
Glaukos (NYSE:GKOS – Get Free Report) last released its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.50) EPS. As a group, sell-side analysts anticipate that Glaukos will post -1.96 EPS for the current fiscal year.
Insider Buying and Selling
In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The trade was a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at $14,198,425.93. This represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Glaukos
A number of large investors have recently bought and sold shares of the business. Values First Advisors Inc. bought a new position in Glaukos during the third quarter valued at about $25,000. Harvest Fund Management Co. Ltd lifted its holdings in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 860 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after purchasing an additional 486 shares during the last quarter. Fifth Third Wealth Advisors LLC bought a new stake in Glaukos during the second quarter worth approximately $187,000. Finally, KBC Group NV grew its holdings in Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.
Glaukos Company Profile
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Read More
- Five stocks we like better than Glaukos
- What Are Dividend Contenders? Investing in Dividend Contenders
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Using the MarketBeat Dividend Yield Calculator
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- There Are Different Types of Stock To Invest In
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.